GSK sues Pfizer and BioNTech over mRNA billions

26 April 2024
law-trial-judge-large-1-

UK pharma major GSK (LSE: GSK) has launched a lawsuit against Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX).

The suit accuses the companies of breaching GSK mRNA vaccine technology patents in their development of the Comirnaty vaccine for COVID-19. The jab swiftly became a top-selling pharma product to help the world to move on from the pandemic, earning Pfizer $43 billion in global revenue in one year alone.

GSK claims that the research in question was conducted by Novartis (NOVN: VX) scientists. Under the leadership of vaccinologist Christian Mandl, their work focused on developing mRNA vaccines. The London-based company acquired rights to the technology in 2015.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology